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Abstract
Background: A controlled, randomised, and blinded trial performed on a conventional French farrow-to-finish farm
compared the efficacy of a one-shot bivalent ready to use vaccine, Porcilis® PCV M. Hyo (group PCVM), to that of
two commercial vaccines (Ingelvac® Circoflex® + Ingelvac® Mhyo, group ICIM), and to a placebo (group CTL), in
preventing the health and economic impacts of Porcine Respiratory Disease Complex (PRDC).
Material & Methods: In this small-scale clinical study, all piglets in each group were administered the vaccine/
placebo at weaning age (27 days old). Piglets from either of the three groups were bled at regular intervals from
3 weeks of age until slaughter, in order to assess the infection by the main PRDC infectious agents: Mycoplasma
hyopneumoniae, PCV2 and PRRSV. Performance, lung checks and slaughter data were collected and analysed.
Results: PCV2 viremia was significantly reduced in both vaccinated groups as compared to the placebo group.
Lung lesion score was significantly lower in group PCVM, as compared to groups CTL and ICIM. Average daily
weight gain during the finishing period was not significantly different between both vaccinated groups and was
significantly higher than in the placebo group (849 g/d in the latter). Carcass results provided a numerical
advantage to PCVM group, through improved part of production eligible for premium payment, and superior
farmer income; this was a trend and did not reach significance.
Conclusion: The one-shot bivalent vaccine Porcilis® PCV M Hyo proved to be efficacious and convenient to use in
a field context of active PCV2 and M. hyopneumoniae infections.
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Background and regional context
The term Porcine Respiratory Disease Complex (PRDC)
describes pneumonia of multiple, combined causal
factors (environmental, management and infectious risk
factors play variable roles), resulting in clinical disease
and reduced growth over the finishing phase of pig
farming (15 to 20 weeks of age) [1]. This multifaceted
respiratory condition in fattening pigs can be controlled
through the efficient prevention and correction of the
relevant risk factors identified by the practitioner of the
corresponding farm. In Western France (Brittany), where
60% of the national swine production is concentrated,
PRDC components have been extensively studied,
regarding both non-infectious [2] and infectious [3] risk
factors. The former cross-sectional study evidenced that-
under French farming conditions, pneumonia and
pleuritis risk factors are mostly different, except for an
inappropriate ventilation programme [2]. Regarding in-
fectious risk factors, the respective part of pathogens in
PRDC can vary with geographic locations, for instance
most of France, with the exception of its Western part,
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is free of PRRS, while Switzerland is free of Mycoplasma
hyopneumoniae. For Western France, pathogens found
to have a prominent role in PRDC were: Mycoplasma
hyopneumoniae, Porcine Reproductive and Respiratory
Syndrome Virus (PRRSV) and Swine influenza virus
(SIV) H1N1, with porcine circovirus type 2 (PCV2)
seeming less dominant in the pneumonia-like gross le-
sions, although it might play a role [2]. Extensive pleuri-
tis lesions were solely found significantly associated with
the combination of Actinobacillus pleuropneumoniae
serotype 2 and PRRSV. In well-performing French farms,
the ventilation programme is checked daily by the
farmer, and controlled on a monthly basis by trained
technicians. The control of infectious risk factors is
mostly performed through vaccination (see [4] for a re-
view). However, even though vaccination against enzo-
otic pneumonia is widely implemented, pneumonia-like
lesions frequency and detection of M. hyopneumoniae
remain elevated [5]. Also, it has been assessed that,
under Brittany’s farming conditions, there is a significant
(p < 0.001) negative correlation between pneumonia
score and growth [6], with a 0.7% loss of average daily
weight gain (ADWG) for each point of pneumonic lung
score increase (“Madec” lung scoring is performed on a
1–28 scale) [7]. Farmers are aware of these facts and are
therefore eager to challenge the respiratory disease vac-
cine strategy implemented in their farm in order to
benefit from any possible improvement of PRDC
control.
Several vaccines against respiratory/systemic infectious
agents, which have been evaluated by the European medi-
cines agency (EMA), have recently reached the European
market. Among those is, the first ready-to-use bivalent
vaccine against PCV2 and Mycoplasma hyopneumoniae,
Porcilis® PCV M Hyo, with efficacy data published by
EMA in its European public assessment report.1
The present clinical study provides further evidence of
the field efficacy of this vaccine.
Case farm and trial setting
In December 2014, a conventional 450-sow French
farrow-to-finish swine farm with no history of clinical
PCV2-associated disease was suggested by its practi-
tioner to our clinical study team as being eligible for a
field trial on PCV2 and Mycoplasma hyopneumoniae
vaccine efficacy. The farm is located in Brittany, in a
high-density farming area (Côtes-d’Armor). A pilot sur-
vey was implemented to assess the circulation of PCV2
and M. hyopneumoniae in the herd.
PCV2 serology (in-house test, Laboratory for Diagnostic
Solutions Intervet Boxmeer, the Netherlands) was per-
formed on fifteen piglets of three age classes: 4, 12 and
22 weeks of age. Seropositivity rate was found to be in-
creasing with age, i.e. 28–35%, 38–80% and 67–89%
respectively, which was suggestive of an active post-
weaning PCV2 circulation (the herd did not vaccinate
sows against PCV2).
M. hyopneumoniae serology (IDEXX M. hyo Ab Test)
was performed on fifteen 21-week old pigs, of which
87% were found positive. Although enzootic pneumonia
vaccination was routinely performed at weaning on this
farm, such high seropositivity rate is strongly suggestive
of active M. hyopneumoniae infection in the fattening
period, on a one-site production system [8]. Further-
more, a lung check was performed at the slaughterhouse
in December 2014, which confirmed that 83% of the 23
controlled pigs had pneumonia lesions, a mean lung le-
sion score (LLS) of 8.4 (‘Madec’ scoring method, on 28,
see [6]) and a median LLS of 8.0. Together, these results
supported an active M. hyopneumoniae infection in the
fattening unit.
The PRRS status of the farm had been recently deter-
mined by the farm veterinarian, with seropositive sows
and pigs becoming infected from 10 weeks of age on-
wards. PRRSV infection was controlled in the female
herd by priming gilts (quarantine) with a modified live
vaccine, and boosts at regular intervals with an inacti-
vated vaccine. Serology performed during the trial later
confirmed that all piglets seroconverted by 14 weeks of
age (data not shown). The same was true for Haemophi-
lus parasuis (all pigs seroconverted by week 22), while
no seroconversion was measured against Actinobacillus
pleuropneumoniae, nor SIV (H1N1, H1N2 and H3N2).
Taken together, these results evidenced the presence of
PRDC, in compliance with both its clinical expression
and the association of pathogens described by Fablet et
al. in Western France [2]. This farm was among the bet-
ter half of the farms belonging to the same production
cooperative (see Table 1), and the producer accepted his
practitioner’s suggestion to add PCV2 valence to the pig-
lets’ vaccination schedule and to compare two options to
vaccinate concurrently against M. hyopneumoniae and
PCV2: a one-shot bivalent ready-to-use (RTU) and a
combination of two commercial vaccines applied in two
separate injections. This trial was to be carried out ac-
cording to a controlled, randomised, and blinded design,
upon completion of the informed consent form by the
farmer.
Four days before the start of the trial (d-4), 498
healthy suckling piglets within the same farrowing
batch were weighed, sexed and individually identified.
On d0, these piglets were on average 26.6 days old; they
were randomly assigned to one of three treatment
groups (see below) taking into account the sex (one
randomisation list for each sex), the litter, and the
weight (sorted in a random list by sow and weight).
They were allocated as they came to hand, until the re-
quired number of piglets was reached. In 15 litters,
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three of the selected piglets (one per treatment group)
of comparable girth (corpulence) were further selected
for blood sampling and received an additional ear tag,
of a different shape and colour. Individual identification
of each included piglet allows considering the animal as
a statistical unit.
On day 0 (10th of March 2015), all piglets were
injected according to their allocated group; blood sam-
pling was also performed. After these procedures, piglets
were placed back in their pen of origin, irrespective of
their treatment group.
– Group CTL (control): piglets (n = 165) were injected
in the neck with saline as placebo (2 ml, via the
intramuscular route).
– Group PCVM: piglets (n = 166) were injected in the
neck with the one-shot bivalent RTU vaccine
Porcilis® PCV M Hyo (2 ml, via the intramuscular
route).
– Group ICIM: piglets (n = 167) were injected with
both vaccines Ingelvac® CircoFLEX® and Ingelvac®
M Hyo, in compliance with the product’s
specifications2: two injections (1 and 2 ml,
respectively) were administered via the IM route on
the same side of the neck of the piglets.
All vaccine injections, blood sampling and weighing
manipulations of piglets/pigs were performed by trained
investigators, from a dedicated intervention team. All
other farm routines were performed-without change, by
stockmen.
Assessment of vaccine efficacy
To assess the efficacy of vaccination, the following pri-
mary parameters were used: for PCV2 protection, PCV2
viremia (quantitative PCR genomic load); for M.
hyopneumoniae infection, lung lesion score (LLS) at
slaughter; for both pathogens, average daily weight gain
(ADWG) over the finishing period (pigs were individu-
ally weighed on the farm before departure to slaughter,
on the 15th and 16th of July). The secondary efficacy
parameters included overall ADWG and mortality
(between vaccination and slaughter, including total
condemnation).
At inclusion, there were no statistically significant
differences in the sex ratio of pigs within each group (p =
0.998, Pearson Chi-square), nor in live-weight (p = 0.578,
least-square means). On this farm, piglets are routinely
weaned at 28 days of age, then spend 2 weeks in a nursery
room before entering pre-fattening for a 5-week period.
At 11 weeks of age, they are transferred to the finishing
rooms. At this age, there were no significant differences in
average live-weight between groups (p = 0.534, analysis of
variance). There was, however, a significant difference be-
tween groups for the average daily weight gain (ADWG)
over that finishing period: PCVM group had a significantly
higher ADWG than the CTL group (p = 0.011, analysis of
variance). These results are detailed in Table 2.
To assess PCV2 viremia, one piglet per litter in each
group was bled at regular intervals (4, 7, 11, 14, 18 and
22 weeks of age). Testing was performed at the Labora-
tory for Diagnostic Solutions Intervet Boxmeer, the
Netherlands, with an in-house quantitative PCR (detec-
tion limit of 2 log10 copies per μl DNA extract). No
PCV2 genome was found in the blood of piglets from
PCVM and ICIM groups, at any age sampled. Con-
versely, in CTL group, PCV2 viremia appeared in 20% of
the sampled 11-week old piglets and was detectable in
94% of 14-week old piglets (see Fig. 1). Area Under the
Curve (AUC) value was 14.0 (group CTL), 0.2 (group
PCVM) and 0.5 (group ICIM). AUC was highly signifi-
cantly lower in each vaccinated group as compared to
the CTL group (in each case, p < 0.0001, Anova).
Lung check was performed at the slaughterhouse for a
subset of pigs in each group (55 to 69 pigs per group).3
Lung scoring was performed individually according to
the method established by Goodwin [9]. The mean lung
lesion score of group PCVM was found to be lower, with
a significant difference (p = 0.007, Kruskal-Wallis test,
see Fig. 2), compared with the 2 other groups. Also, the
proportion of lungs with pneumonic lesions was signifi-
cantly higher in both group CTL and group ICIM, as
compared to group PCVM (p = 0.021, Pearson Chi-
square, see Fig. 3). Taken together, these results are in
Table 1 Comparative performance results for the trial farm, with reference to the production cooperative it belongs to, and to
swine producers in the same region (farm's data are in bold)
Study farm, average
2015 performance
Average performance of all members
of the same cooperative, 2015
Average performance of
all producers in Brittany, 2015
Number of pigs produced per sow per year 28.5 24.4 23.2
Number of kg liveweight produced per sow per year 3,439 2,809 2,699
Feed conversion ratio (wean to finish) 2.80 2.81 2.80
Mortality rate (includes condemnation at slaughterhouse) 4.9% 5.9% 6.2%
Normalised ADWG 8–30 kg liveweight (g/d) 505 498 478
Normalised ADWG 30–115 kg liveweight (g/d) 798 799 815
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favour of the use of multivalent vaccines/vaccine pro-
grammes in prevention of PRDC. Under the condition
that the selected valences are adapted to the local com-
bination of the pathogens implied in PRDC, this trial
adds-up to the growing body of evidence of the efficacy
of this intervention, as has recently been demonstrated
in Germany [10] against PCV2 and M. hyopneumoniae
or Korea [11] against PCV2 and PRRSV, with a more
limited number of primary parameters.
Slaughter data were sent by the slaughterhouse to the
farmer under an electronic format (Microsoft Excel®
tabs) and were compiled with the farmer’s agreement.
These complete data provided secondary parameters:
mortality rate (which includes full carcass condemnation
at the slaughterhouse), average age at slaughter, average
net carcass weight (excluding the condemned pieces),
average amount of quality premiums for which the
farmer was eligible and average per-pig income (calcula-
tion includes vaccination costs). These data are detailed
in Table 3. Statistical significance was not reached be-
tween any groups for any of these parameters. There
was however a trend for improved revenue paid to the
farmer in group PCVM (p = 0.08), through a larger num-
ber of pigs eligible for a premium (p = 0.07). A larger
number of pigs in the trial may have resulted in statis-
tical significance. This latter observation is in parallel
with the recent assessment of the antimicrobial meta-
phylaxis in fattening pigs affected by PRDC in PRRS-free
Table 2 Numeric data, results, and statistical analysis for each trial group, measures performed over the production period












(number of dead pigs)
Group CTL 6.80 (165) 29.56 96.9 438 849.6a 2.4% (4)
Group PCVM 6.79 (166) 28.96 99.0 426 880.6b 6.0% (9)
Group ICIM 6.66 (167) 29.14 97.9 432 867.2ab 3.6% (4)
Total (498) NC NC NC NC NC
p value 0.578 0.534 0.193 0.424 0.011 0.218
Test used Anova Anova Anova Anova Anova Chi-square
Values with different letters within the same column are statistically significantly different
NC not calculated
Fig. 1 Proportion of piglets with a detectable PCV2 genomic load in serum (qPCR) in each group, across ages
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herds [12], where growth retardation was only compen-
sated in the lighter pigs in the studied cohort, i.e. where
the intervention has limited positive impact in terms of
animal health as well as of financial benefit.
Conclusion
Pigs in the control group presented an elevated PCV2
viremia between 11 and 22 weeks of age. Upon slaughter,
more than 80% of them presented M. hyopneumoniae-like
lung lesions, with average LLS of 5.9. These elements con-
firm that both PRDC pathogens were actively circulating
in the trial farm. A highly significant prevention of PCV2
viremia was observed in both vaccinated groups.
Compared to the group ICIM, the group PCVM had
significantly better outcome regarding the frequency of
pneumonia (−20%) and LLS (3.1 vs. 6.3). Furthermore,
the group PCVM also produced an improved ADWG in
fattening (+13 g/d), carcasses quality premium (+1,8 €
cts/kg) and average per-pig income (+2,6 €); these favor-
able results neared significance. In this field trial, Porci-
lis® PCV M Hyo proved to be efficacious in protecting
piglets against both PCV2 viremia and the impact of M.
hyopneumoniae infection, in a context of active PRDC
and PCV2 infection.
Endnotes




Fig. 2 Average lung lesion score (scoring according to Goodwin) in each trial group, in a subset of 179 pigs, from the 498 pigs included
Fig. 3 Percentage of pigs with pneumonia, in each trial group, in a subset of 179 pigs, from the 498 pigs included
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2For CircoFLEX®, see at http://www.ema.europa.eu/docs/
en_GB/document_library/EPAR_-_Product_Information/vet
erinary/000126/WC500062388.pdf. For Ingelvac® M. Hyo,
see French SPCs at http://www.ircp.anmv.anses.fr/rcp.aspx?-
NomMedicament=INGELVAC+M.HYO
3Due to social contemporary social disruption at the
time of the trial, slaughterhouse of destination of some
batches has been changed at the last minute, without the
lung check personnel being warned. Some animals have
been missed, in each trial group.
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(€ cent per kg)
Income per piga
(€/head)
Group CTL 69 5.9a 82.6a 187.1 90.6 13.5 139.6
Group PCVM 55 3.1b 65.5b 184.5 91.6 14.1 141.6
Group ICIM 55 6.3a 85.5a 185.6 91.0 12.3 139.0
p value NC 0.007 0.021 0.162 0.246 0.071 0.082
Test used NA Kruskal-Wallis Pearson Chi-2 Kruskal-Wallis Anova Anova Anova
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